Replies to post #163931 on Biotech Values

[ciotera]

So you are saying it's not worth their time to run a study in the only genotype this combo works well in?

That's the genotype that it works BEST in, does not necessarily mean it's the most attractive opportunity.

[jq1234]

Precisely because they had good data for GT2 already, they don't need anymore. They need longer treatment duration data for naive GT3, while they only had ph2 data for this combo in GT1, they were treatment duration of either 12 weeks or 24 weeks I believe. So it makes perfect sense they only run this ph3b trial in GT1/3.